199 related articles for article (PubMed ID: 10024074)
61. Effect of exogenously administered glucagon on plasma glucose levels in totally depancreatized dogs.
Nishimura I; Sudo T; Konishi K; Suzuki T; Tobe T; Nakagawa M; Nakase A
Gastroenterol Jpn; 1978; 13(6):468-79. PubMed ID: 748092
[TBL] [Abstract][Full Text] [Related]
62. Exercise-induced fall in insulin: mechanism of action at the liver and effects on muscle glucose metabolism.
Zinker BA; Mohr T; Kelly P; Namdaran K; Bracy DP; Wasserman DH
Am J Physiol; 1994 May; 266(5 Pt 1):E683-9. PubMed ID: 7911275
[TBL] [Abstract][Full Text] [Related]
63. Interaction of glucagon and epinephrine in the control of hepatic glucose production in the conscious dog.
Gustavson SM; Chu CA; Nishizawa M; Farmer B; Neal D; Yang Y; Donahue EP; Flakoll P; Cherrington AD
Am J Physiol Endocrinol Metab; 2003 Apr; 284(4):E695-707. PubMed ID: 12626324
[TBL] [Abstract][Full Text] [Related]
64. Assessment of hepatic sensitivity to glucagon in NIDDM: use as a tool to estimate the contribution of the indirect pathway to nocturnal glycogen synthesis.
Nielsen MF; Wise S; Dinneen SF; Schwenk WF; Basu A; Rizza RA
Diabetes; 1997 Dec; 46(12):2007-16. PubMed ID: 9392488
[TBL] [Abstract][Full Text] [Related]
65. Role of the hepatic sympathetic nerves in the regulation of net hepatic glucose uptake and the mediation of the portal glucose signal.
Dicostanzo CA; Dardevet DP; Neal DW; Lautz M; Allen E; Snead W; Cherrington AD
Am J Physiol Endocrinol Metab; 2006 Jan; 290(1):E9-E16. PubMed ID: 16105863
[TBL] [Abstract][Full Text] [Related]
66. Extrapancreatic glucagon in control of glucose turnover in depancreatized dogs.
Ross G; Lickley L; Vranic M
Am J Physiol; 1978 Feb; 234(2):E213-19. PubMed ID: 623297
[TBL] [Abstract][Full Text] [Related]
67. Effects of selective insulin or glucagon deficiency on glucose turnover.
Lickley HL; Ross GG; Vranic M
Am J Physiol; 1979 Mar; 236(3):E255-62. PubMed ID: 426056
[TBL] [Abstract][Full Text] [Related]
68. Effects of free fatty acids and glycerol on splanchnic glucose metabolism and insulin extraction in nondiabetic humans.
Shah P; Vella A; Basu A; Basu R; Adkins A; Schwenk WF; Johnson CM; Nair KS; Jensen MD; Rizza RA
Diabetes; 2002 Feb; 51(2):301-10. PubMed ID: 11812736
[TBL] [Abstract][Full Text] [Related]
69. Assessment of hepatic insulin action in obese type 2 diabetic patients.
Staehr P; Hother-Nielsen O; Levin K; Holst JJ; Beck-Nielsen H
Diabetes; 2001 Jun; 50(6):1363-70. PubMed ID: 11375337
[TBL] [Abstract][Full Text] [Related]
70. Catecholamine responses and their interactions with other glucoregulatory hormones.
Vranic M; Gauthier C; Bilinski D; Wasserman D; El Tayeb K; Hetenyi G; Lickley HL
Am J Physiol; 1984 Aug; 247(2 Pt 1):E145-56. PubMed ID: 6147092
[TBL] [Abstract][Full Text] [Related]
71. Glucagon-mediated impairments in hepatic and peripheral tissue nutrient disposal are not aggravated by increased lipid availability.
Chen SS; Santomango TS; Williams PE; Lacy DB; McGuinness OP
Am J Physiol Endocrinol Metab; 2009 May; 296(5):E1172-8. PubMed ID: 19208853
[TBL] [Abstract][Full Text] [Related]
72. The effect of portal and peripheral insulin delivery on carbohydrate and lipid metabolism in a miniature pig model of human IDDM.
Canavan JP; Flecknell PA; New JP; Alberti KG; Home PD
Diabetologia; 1997 Oct; 40(10):1125-34. PubMed ID: 9349592
[TBL] [Abstract][Full Text] [Related]
73. Role of FFA-glucose cycle in glucoregulation during exercise in total absence of insulin.
Yamatani K; Shi ZQ; Giacca A; Gupta R; Fisher S; Lickley HL; Vranic M
Am J Physiol; 1992 Oct; 263(4 Pt 1):E646-53. PubMed ID: 1415684
[TBL] [Abstract][Full Text] [Related]
74. Non-esterified fatty acids and the liver: why is insulin secreted into the portal vein?
Bergman RN
Diabetologia; 2000 Jul; 43(7):946-52. PubMed ID: 10952470
[TBL] [Abstract][Full Text] [Related]
75. Regulation of glucose production by NEFA and gluconeogenic precursors during chronic glucagon infusion.
McGuinness OP; Ejiofor J; Audoly LP; Schrom N
Am J Physiol; 1998 Sep; 275(3):E432-9. PubMed ID: 9725809
[TBL] [Abstract][Full Text] [Related]
76. Peripheral effects of insulin dominate suppression of fasting hepatic glucose production.
Ader M; Bergman RN
Am J Physiol; 1990 Jun; 258(6 Pt 1):E1020-32. PubMed ID: 2193527
[TBL] [Abstract][Full Text] [Related]
77. Improved postprandial metabolic control after subcutaneous injection of a short-acting insulin analog in IDDM of short duration with residual pancreatic beta-cell function.
Pampanelli S; Torlone E; Ialli C; Del Sindaco P; Ciofetta M; Lepore M; Bartocci L; Brunetti P; Bolli GB
Diabetes Care; 1995 Nov; 18(11):1452-9. PubMed ID: 8722069
[TBL] [Abstract][Full Text] [Related]
78. Differential sensitivity of glycogenolysis and gluconeogenesis to insulin infusions in dogs.
Chiasson JL; Liljenquist JE; Finger FE; Lacy WW
Diabetes; 1976 Apr; 25(4):283-91. PubMed ID: 1269837
[TBL] [Abstract][Full Text] [Related]
79. Chronic physiologic hyperinsulinemia impairs suppression of plasma free fatty acids and increases de novo lipogenesis but does not cause dyslipidemia in conscious normal rats.
Koopmans SJ; Kushwaha RS; DeFronzo RA
Metabolism; 1999 Mar; 48(3):330-7. PubMed ID: 10094109
[TBL] [Abstract][Full Text] [Related]
80. Exogenous insulin replacement in type 2 diabetes reverses excessive hepatic glucose release, but not excessive renal glucose release and impaired free fatty acid clearance.
Woerle HJ; Popa E; Dostou J; Welle S; Gerich J; Meyer C
Metabolism; 2002 Nov; 51(11):1494-500. PubMed ID: 12404204
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
